*“Preferred” means that QULIPTA^® is on a preferred tier or otherwise has preferred status on the plan’s formulary.

Source: Managed Markets Insight & Technology, LLC, a trademark of MMIT. Data as of January 2023 and subject to change.

Data are not a guarantee of coverage, or partial or full payment, by any payer listed. Actual benefits determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. AbbVie does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.

INDICATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS
The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue.

DRUG INTERACTIONS
Strong CYP3A4 Inhibitors: 10 mg once daily.
Strong and Moderate CYP3A4 Inducers: 30 mg or 60 mg once daily.
OATP Inhibitors: 10 mg or 30 mg once daily.

USE IN SPECIFIC POPULATIONS
Severe Renal Impairment or End-Stage Renal Disease: 10 mg once daily.
Avoid use in patients with severe hepatic impairment.

Please see full Prescribing Information.

© 2023 AbbVie. All rights reserved.
QULIPTA^® and its design are registered trademarks of Allergan Pharmaceuticals International Limited, an AbbVie company.
US-QLP-230069  03/23